Literature DB >> 26014718

The Impact of Preoperative Radiation Therapy on Locoregional Recurrence in Patients with Stage IV Rectal Cancer Treated with Definitive Surgical Resection and Contemporary Chemotherapy.

Bindu V Manyam1, Ismail H Mallick, May M Abdel-Wahab, Chandana A Reddy, Feza H Remzi, Matthew F Kalady, Ian Lavery, Shlomo A Koyfman.   

Abstract

PURPOSE: Definitive resection of primary rectal cancers is frequently incorporated, with or without preoperative radiotherapy and perioperative chemotherapy, in the management of selected patients with metastatic rectal adenocarcinoma. This study reviews the impact of preoperative radiotherapy and perioperative chemotherapy on locoregional recurrence and overall survival in these patients. METHODS AND MATERIALS: This retrospective study with an Institutional Review Board (IRB) waiver included 109 patients with metastatic rectal adenocarcinoma who underwent definitive primary resection between 1998 and 2011. In addition to resection, 64 patients were treated with preoperative radiotherapy and perioperative chemotherapy and 45 patients were treated with perioperative chemotherapy alone. Radiotherapy dose was typically 50.4 Gy. Baseline variables were compared using chi-square and unpaired t tests. Overall survival was calculated using Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox proportional hazards regression.
RESULTS: There were no significant baseline differences between the two groups. There was no significant difference in locoregional recurrence (10.9 vs. 11.1%; p = 0.90) or overall survival (34.5 vs. 34.8 months; p = 0.89) for patients treated with preoperative radiotherapy compared to those treated with perioperative chemotherapy alone, respectively. Patients who underwent radiotherapy were less likely to have a positive margin (10.9 vs. 20.0%; p = 0.19), lymphovascular invasion (32.8 vs. 53.3%; p = 0.03), and pathologic stage N2 disease (25.0 vs. 42.2%; p = 0.02). Grade 2 postoperative complications were more common in the preoperative radiotherapy group (32.8 vs. 15.6%; p = 0.04). Multivariate analysis demonstrated that patients with poorly differentiated tumors (HR 2.19; p = 0.009) and those that did not undergo liver-directed therapy (HR 2.20; p = 0.005) had inferior survival.
CONCLUSIONS: Locoregional recurrence is modest in patients with metastatic rectal adenocarcinoma receiving definitive primary resection, irrespective of the use of radiotherapy. Preoperative radiotherapy may enhance pathologic downstaging at the expense of increased grade 2 postoperative complications. Its use should be reserved for patients at high risk for locoregional recurrence.

Entities:  

Mesh:

Year:  2015        PMID: 26014718     DOI: 10.1007/s11605-015-2861-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.

Authors:  Ho Jung An; Chang Sik Yu; Sung-Cheol Yun; Byung Woog Kang; Yong Sang Hong; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Jin Hong Park; Jong Hoon Kim; Yoon-Koo Kang; Jin Cheon Kim; Tae Won Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-31       Impact factor: 7.038

2.  Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?

Authors:  Christina Cellini; Steven R Hunt; James W Fleshman; Elisa H Birnbaum; Andrew J Bierhals; Matthew G Mutch
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

3.  Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience.

Authors:  P R Thomas; A S Lindblad
Journal:  Radiother Oncol       Date:  1988-12       Impact factor: 6.280

4.  Outcomes of resection of stage IV rectal cancer with mesorectal excision.

Authors:  Wai Lun Law; Kin Wah Chu
Journal:  J Surg Oncol       Date:  2006-06-01       Impact factor: 3.454

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

7.  Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis.

Authors:  Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

8.  Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site.

Authors:  Lia Assumpcao; Michael A Choti; Ana Luiza Gleisner; Richard D Schulick; Michael Swartz; Joseph Herman; Susan L Gearhart; Timothy M Pawlik
Journal:  Arch Surg       Date:  2008-08

9.  Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.

Authors:  Sabine Venderbosch; Johannes H de Wilt; Steven Teerenstra; Olaf J Loosveld; Aart van Bochove; Harm A Sinnige; Geert-Jan M Creemers; Margot E Tesselaar; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

10.  Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.

Authors:  Leif Schiffmann; Nicole Wedermann; Michael Gock; Friedrich Prall; Gunther Klautke; Rainer Fietkau; Bettina Rau; Ernst Klar
Journal:  BMC Surg       Date:  2013-09-30       Impact factor: 2.102

View more
  7 in total

1.  Neoadjuvant Radiotherapy Versus No Radiotherapy for Stage IV Rectal Cancer: a Systematic Review and Meta-analysis.

Authors:  Ryan Anthony F Agas; Lester Bryan A Co; J C Kennetth M Jacinto; Kelvin Ken L Yu; Paolo G Sogono; Warren R Bacorro; Teresa T Sy Ortin
Journal:  J Gastrointest Cancer       Date:  2018-12

2.  Predicting Overall Survival in Patients with Metastatic Rectal Cancer: a Machine Learning Approach.

Authors:  Beiqun Zhao; Rodney A Gabriel; Florin Vaida; Nicole E Lopez; Samuel Eisenstein; Bryan M Clary
Journal:  J Gastrointest Surg       Date:  2019-08-29       Impact factor: 3.452

Review 3.  Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?

Authors:  Maitham A Moslim; Amir L Bastawrous; D Rohan Jeyarajah
Journal:  J Gastrointest Surg       Date:  2021-06-07       Impact factor: 3.452

4.  The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis.

Authors:  Croix C Fossum; Jasim Y Alabbad; Lindsay B Romak; Christopher L Hallemeier; Michael G Haddock; Marianne Huebner; Eric J Dozois; David W Larson
Journal:  J Gastrointest Oncol       Date:  2017-08

5.  Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer.

Authors:  Haiyang Zhang; Jingjing Duan; Yanjun Qu; Ting Deng; Rui Liu; Le Zhang; Ming Bai; Jialu Li; Tao Ning; Shaohua Ge; Xia Wang; Zhenzhen Wang; Qian Fan; Hongli Li; Guoguang Ying; Dingzhi Huang; Yi Ba
Journal:  Protein Cell       Date:  2016-01-12       Impact factor: 14.870

6.  The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma.

Authors:  Rui Liu; Haiyang Zhang; Xia Wang; Likun Zhou; Hongli Li; Ting Deng; Yanjun Qu; Jingjing Duan; Ming Bai; Shaohua Ge; Tao Ning; Le Zhang; Dingzhi Huang; Yi Ba
Journal:  Oncotarget       Date:  2015-12-22

7.  Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated With Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study.

Authors:  Dakui Luo; Qi Liu; Ji Zhu; Yanlei Ma; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.